Dapagliflozin and empagliflozin – a new perspective for patients with heart failure with preserved ejection fraction (HFpEF)
Abstract
Introduction and Objective . The aim of this review is to analyze and evaluate the results of studies from the last six years regarding the therapeutic efficacy of SGLT-2 inhibitors – dapagliflozin and empagliflozin – in patients with heart failure with preserved left ventricular ejection fraction (HFpEF). The review includes a detailed discussion of the key studies in this field – DELIVER and EMPEROR-Preserved, Also described are new research directions that focus on understanding the metabolic effects of SGLT-2 inhibitors on the myocardium, and their impact on microcirculation. Review Methods . A literature search was conducted in the PubMed and Web of Science databases, using the inclusion criteria of ‘free full text’ and articles in English published between 2020 – 2025. A total of 139 records were found, of which 35 publications were ultimately included in the review.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.